329187-80-6

Basic information

• Product Name: 2,6-Dichloropurine -9-beta-D-(2'-deoxy-3',5'-di-O-benzoyl-2'-fluoro)arabinoriboside
• Synonyms: 2,6-Dichloropurine -9-beta-D-(2'-deoxy-3',5'-di-O-benzoyl-2'-fluoro)arabinoriboside;2,6-Dichloro-9-(2-deoxy- 2-fluoro-β-D-arabinofuranosyl)-9H-purine;2,6-Dichloro-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-D-arabinofuranosyl)-9H-purine
• CAS NO: 329187-80-6
• Molecular Formula: C₂₄H₁₇Cl₂FN₄O₅
• Molecular Weight: 531.3199832
• Mol File: 329187-80-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,6-Dichloropurine -9-beta-D-(2'-deoxy-3',5'-di-O-benzoyl-2'-fluoro)arabinoriboside(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dichloropurine -9-beta-D-(2'-deoxy-3',5'-di-O-benzoyl-2'-fluoro)arabinoriboside(329187-80-6)
• EPA Substance Registry System: 2,6-Dichloropurine -9-beta-D-(2'-deoxy-3',5'-di-O-benzoyl-2'-fluoro)arabinoriboside(329187-80-6)

Safety Data

• Hazardous Substances Data: 329187-80-6(Hazardous Substances Data)

Usage

General Description

2,6-Dichloropurine -9-beta-D-(2'-deoxy-3',5'-di-O-benzoyl-2'-fluoro)arabinoriboside is a chemical compound that is derived from purine and arabinoriboside. It is a nucleoside analog that has potential therapeutic applications in the treatment of cancer and viral infections. The compound has been studied for its antiviral and anticancer properties, and it has shown promise in preclinical research. Its structure includes a purine base with two chlorine atoms, and a modified arabinoribose sugar with benzoyl and fluoro groups. Further research on this compound may lead to the development of novel drugs for various medical conditions.

Upstream product

• 5451-40-1 2,6 dichloropurine 
• 1067137-03-4 3,5-di-O-benzoyl-2-deoxy-2-fluoro-α-D-arabinofuranosyl bromide 
• 97614-43-2 1,3,5-tri-O-benzoyl-2-deoxy-2-fluoro-α-D-arabinofuranose 
• 97614-44-3 2-deoxy-2-fluoro-3,5-di-O-benzoyl-α-D-arabinofuranosyl bromide 
• 5451-40-1 2,6-dichloro-7H-purine 
• 98855-71-1 ((2R,3R,4S)-3-(benzoyloxy)-5-bromo-4-fluorotetrahydrofuran-2-yl)methyl benzoate 

Downstream Products

• 355138-50-0 6-amino-2-chloro-9-(2'-deoxy-2'-fluoro-3',5'-di-O-benzoyl-β-D-arabinofuranosyl)-9H-purine 
• 1013918-32-5 C₂₄H₁₇FN₁₀O₅ 
• 20187-82-0 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine 
• 103884-98-6 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-guanine 
• 123318-82-1 clofarabine 
• 103884-97-5 9-(2’-deoxy-2’-fluoro-β-D-arabinofuranos-1’-yl)-2-amino-6-aminopurine 
• 136834-22-5 (2R,3R,4S,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluorotetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite 
• 758705-70-3 2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-6-methoxy-9H-purine 

Relevant articles and documents

Discovery of AB680: A Potent and Selective Inhibitor of CD73

Extracellular adenosine (ADO), present in high concentrations in the tumor microenvironment (TME), suppresses immune function via inhibition of T cell and NK cell activation. Intratumoral generation of ADO depends on the sequential catabolism of ATP by two ecto-nucleotidases, CD39 (ATP → AMP) and CD73 (AMP → ADO). Inhibition of CD73 eliminates a major pathway of ADO production in the TME and can reverse ADO-mediated immune suppression. Extensive interrogation of structure-activity relationships (SARs), structure-based drug design, and optimization of pharmacokinetic properties culminated in the discovery of AB680, a highly potent (Ki = 5 pM), reversible, and selective inhibitor of CD73. AB680 is further characterized by very low clearance and long half-lives across preclinical species, resulting in a PK profile suitable for long-acting parenteral administration. AB680 is currently being evaluated in phase 1 clinical trials. Initial data show AB680 is well tolerated and exhibits a pharmacokinetic profile suitable for biweekly (Q2W) iv-administration in human.

INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION

Compounds that modulate the conversion of AMP to adenosine by 5'- nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5'- nucleotidase, ecto is also provided.

MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF

Compounds that modulate the conversion of AMP to adenosine by 5'- nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5'-nucleotidase, ecto is also provided.